Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3

Next Previous
X
Search
Trial Profile

A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; VALO-D102 (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Male breast cancer; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Sarcoma; Synovial sarcoma; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms START
  • Sponsors Valo Therapeutics

    • Most Recent Events

    • 08 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Sep 2025.
    • 08 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Jun 2025.
    • 29 Nov 2023 According to a Valo therapeutics media release, the company received approval from Germany's PEI (Paul Ehrlich Institute) to extend the tumor types to be treated into two subtypes of sarcoma, synovial and myxoid round cell sarcoma. Third recruitment center has been opened recently in Tubingen.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top